Key result
Low-dose aspirin (75-325 mg/day) increased the risk of gastrointestinal bleeding compared with placebo (OR 1.52; 95% CI 1.32-1.75).
Why the study?
Does low-dose aspirin increase the risk of gastrointestinal bleeding in patients requiring prevention of ischemic, thromboembolic, or cerebrovascular events?
Population
Patients from 9 pooled studies requiring prevention of ischemic, thromboembolic, or cerebrovascular events
Comparison
Low-dose aspirin (75-325 mg/day) vs Placebo
Design
Meta-analysis
Authors
Loading...
Requires weighing GI bleeding risk in low-dose aspirin prescriptions for prevention; reinforces established risk in cardiovascular settings.
Meta-Analysis
Does low-dose aspirin increase the risk of gastrointestinal bleeding in patients requiring prevention of ischemic, thromboembolic, or cerebrovascular events?
Effect estimate: OR 1.52 (95% CI 1.32-1.75)
Low-dose aspirin (75-325 mg/day) significantly increases the risk of gastrointestinal bleeding by approximately 50% compared to placebo in patients receiving it for cardiovascular or cerebrovascular prevention.
Stalnikowicz-Darvasi Ruth (1995) conducted a meta-analysis in Prevention of ischemic, thromboembolic, or cerebrovascular events. Low-dose aspirin vs. Placebo was evaluated on Gastrointestinal bleeding (OR 1.52, 95% CI 1.32-1.75). Low-dose aspirin (75-325 mg/day) increased the risk of gastrointestinal bleeding compared with placebo (OR 1.52; 95% CI 1.32-1.75).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: